Methods of Analyzing Pathways of Colorectal Cancer in Middle East May Be Ineffective
the Cancer Therapy Advisor take:
A majority of Middle Eastern colorectal cancer (CRC) cases was designated as part of the unassigned group, suggesting methods of analyzing molecular pathways may not apply to this ethnic group, according to an article published online in the journal Cancer.
A total of 770 CRC cases were evaluated using molecular characterization for microsatellite instability, BRAF, and KRAS by polymerase chain reaction, and another 500 cases were examined for CpG island methylator phenotype (CIMP) high phenotype.
Results showed 33.4% of CRC cases were comprised of the traditional pathway, 11.6% were the alternate pathway, and 0.8% of CRC cases in the Middle East were characterized as the serrated molecular pathway. The remaining 54.2% of CRC cases were not characterized according to any of the three molecular pathways, and, therefore, they were categorized as the unassigned group.
Furthermore, the molecular pathways were determined to be significantly associated with both tumor site and grade.
A significant survival difference (P=0.0079) was observed in a subset of cases with an unassigned molecular pathway.
The study’s findings suggest that more research is needed regarding the molecular genetic basis of CRC in order to characterize cases of the disease.
A majority of Middle Eastern colorectal cancer cases was designated as part of the unassigned group.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Plastics and Cancer
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer